P033 - LOW SKELETAL MUSCLE MASS PREDICTS LONGER ICU STAY IN PATIENTS UNDERGOING CRS WITH HIPEC: A RETROSPECTIVE COHORT STUDY

P033

LOW SKELETAL MUSCLE MASS PREDICTS LONGER ICU STAY IN PATIENTS UNDERGOING CRS WITH HIPEC: A RETROSPECTIVE COHORT STUDY

R. Festugatto Tartari^1,2,*, T. M. Miola³, G. Arns¹, D. Zaffari⁴, R. Seitenfus⁵

¹Nutrition, Santa Casa de Porto Alegre, Porto Alegre, ²Master's Degree in Food, Nutrition and Health , Unisinos, São Leopoldo, ³Nutrition, AC Camargo Cancer Center, São Paulo, ⁴Master's Degree in Food, Nutrition and Health , Unisinos, ⁵Surgical Oncology, Santa Casa de Porto Alegre, Porto Alegre, Brazil

Rationale: Patients undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) are at high risk for postoperative complications, including infections, organ dysfunction, and prolonged ICU stays. Evidence suggests that low skeletal muscle mass may be associated with adverse clinical outcomes in this population.

Methods: This retrospective cohort study included patients who underwent CRS with HIPEC between January 2021 and April 2024. Skeletal muscle mass was assessed by computed tomography (CT) within 30 days before and after the procedure. Data were extracted from electronic medical records. Clinical outcomes included ICU length of stay, total hospital stay, and 28-day mortality.

Results: Seventy-four patients were included. Patients with low skeletal muscle mass had significantly longer ICU stays (p=0.041). No statistically significant associations were found between muscle mass and total hospital length of stay or 28-day mortality.

Conclusion: Low skeletal muscle mass, as measured by CT, was associated with longer ICU length of stay in patients undergoing CRS with HIPEC. Muscle mass assessment in the perioperative period may serve as a valuable tool for risk stratification and guiding individualized interventions to improve recovery in this high-risk population.

References: Dietz MV, et al. The Impact of Low Skeletal Muscle Mass on Short- and Long-Term Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2022 Sep;29(9):5830-5841.

Di Giorgio A, et al. The prognostic value of skeletal muscle index on clinical and survival outcomes after cytoreduction and HIPEC for peritoneal metastases from colorectal cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2022 Mar;48(3):649-656.

Disclosure of Interest: None declared